APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation is a phase 2, randomised interventional study registered as NCT04858334 by National Cancer Institute (NCI), with a registry enrolment figure of 152 participants, started 2021-06-22 and due to reach its primary completion in 2027-10-31. Interventions recorded: Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib; Placebo Administration. Conditions listed: Pancreatic Acinar Cell Carcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Squamous Cell Carcinoma; Resectable Pancreatic Acinar Cell Carcinoma; Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenosquamous Carcinoma; Resectable Pancreatic Carcinoma. Primary outcome: Improvement in relapse-free survival (RFS). Pancreatic eligibility wording from the registry: "* Patient must have a diagnosis of pancreatic cancer and have successfully undergone a curative intent surgical resection and must have no evidence of recurrent disease as determined by the investigator". Sites: Israel, Puerto Rico, United States. No results are recorded here; the registry entry is the source.